Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver

被引：5
|
作者：
Yang, Ranyao [1 ,2 ]
Xu, Aimin [1 ,2 ,3 ]
Kharitonenkov, Alexei [4 ]
机构：
[1] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Pokfulam, Hong Kong 999077, Peoples R China
[2] Univ Hong Kong, Dept Med, Pokfulam, Hong Kong 999077, Peoples R China
[3] Univ Hong Kong, Dept Pharmacol & Pharm, Pokfulam, L8-39,Lab Block,21 Sassoon Rd, Hong Kong 999077, Peoples R China
[4] AK Biotechnol LLC, 430 Amador Ln, W Palm Beach, FL 33401 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2022年 / 107卷 / 01期
关键词：
fibroblast growth factor 21 (FGF21); hypertriglyceridemia; obesity; nonalcoholic fatty liver diseases (NAFLD); metabolism;
D O I：
10.1210/clinem/dgab686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E417 / E419
页数：3
相关论文
共 50 条
  • [21] FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy
    Shenglong Zhu
    Yunzhou Wu
    Xianlong Ye
    Lei Ma
    Jianying Qi
    Dan Yu
    Yuquan Wei
    Guangxiao Lin
    Guiping Ren
    Deshan Li
    Molecular and Cellular Biochemistry, 2016, 420 : 107 - 119
  • [22] Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys
    Veniant, Murielle M.
    Komorowski, Renee
    Chen, Ping
    Stanislaus, Shanaka
    Winters, Katherine
    Hager, Todd
    Zhou, Lei
    Wada, Russell
    Hecht, Randy
    Xu, Jing
    ENDOCRINOLOGY, 2012, 153 (09) : 4192 - 4203
  • [23] FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy
    Zhu, Shenglong
    Wu, Yunzhou
    Ye, Xianlong
    Ma, Lei
    Qi, Jianying
    Yu, Dan
    Wei, Yuquan
    Lin, Guangxiao
    Ren, Guiping
    Li, Deshan
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2016, 420 (1-2) : 107 - 119
  • [24] Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study
    Dong, Jennifer Q.
    Rossulek, Michelle
    Somayaji, Veena R.
    Baltrukonis, Daniel
    Liang, Yali
    Hudson, Krischan
    Hernandez-Illas, Martha
    Calle, Roberto A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) : 1051 - 1063
  • [25] Metabolic, biochemical, histopathological and transcriptomic effects of long-acting FGF21 analogue in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
    Nielsen, Malte H.
    Oro, Denise
    Hansen, Henrik B.
    Gillum, Matthew
    Feigh, Michael
    JOURNAL OF HEPATOLOGY, 2022, 77 : S669 - S669
  • [26] Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
    Yilmaz, Yusuf
    Eren, Fatih
    Yonal, Oya
    Kurt, Ramazan
    Aktas, Bilge
    Celikel, Cigdem Ataizi
    Ozdogan, Osman
    Imeryuz, Nese
    Kalayci, Cem
    Avsar, Erol
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (10) : 887 - 892
  • [27] Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats
    Tillman, Erik J.
    Brock, William J.
    Rolph, Tim
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (07) : 1384 - 1394
  • [28] A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway
    Bao, Lichen
    Yin, Jun
    Gao, Wen
    Wang, Qun
    Yao, Wenbing
    Gao, Xiangdong
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (16) : 3379 - 3393
  • [29] Discovery of a Long-Acting Parathyroid Hormone 1-34 Analogue to Treat Hypoparathyroidism
    Ruan, Sida
    Yang, Guiying
    Dong, Yuanzhen
    Shangguan, Wenwen
    Lu, Weigen
    MOLECULAR PHARMACEUTICS, 2021, 18 (09) : 3260 - 3271
  • [30] A novel circular RNA therapy expressing a long-acting FGF21 analog protein reversed obesity, insulin resistance, and steatosis in mouse models
    Cao, Rui
    Wan, Haitao
    Zeng, Jing
    Gao, Lu
    JOURNAL OF HEPATOLOGY, 2024, 80 : S573 - S573
12345